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• Pathological complete response (pCR) to neoadjuvant
systemic therapy (NST) in patients with breast cancer (BC)
predicts long-term outcomes.
• Anaemia is one of the most common side effects of
cytotoxic drugs. Biologically, anaemia induces adaptive
responses due to the low intra-tumoral oxygen levels that
may be responsible for increase chemotherapy resistance.
In literature, data regarding this issue are lacking.
• To evaluate the influence of anaemia throughout
treatment course on tumour shrinkage induced by NST.
Patients - 317 patients diagnosed with stage I-III BC treated
with NST and with available blood tests were included.
Patients and tumor characteristics and treatments
information were collected. We focused on Haemoglobin
(Hb) level (at baseline, at the end of NST, drop in Hb
throughout treatment and duration of anaemia) and its
correlation with pCR rate. Anaemia was defined as a drop of
Hb under the local limit of normal in women (12 mg/dl).
Statistical analysis - Categorical variables were analyzed
using chi-square test or Fisher's exact test, continuous
variables using t test. Univariate and multivariate analyses
were fit to determinate the association between anaemia
and pCR rate. A p-value < 0.05 was considered statistically
significant; hazard ratio was estimated with 95% of
confidence limits.
• No difference in Hb levels was observed stratifying
patients according to nuclear grade, tumor stage, cancer
subtypes and chemotherapy regimens.
• Median baseline Hb was 13.3 g/dl while median Hb level
at the end of NST was 10 g/dl.
• 31 patients had pre-treatment anaemia. 60% of patients
developed anaemia during NST period.
• In the subgroup of anaemic patients, who had a decrease
in Hb ≥ 2 g/dl from baseline or anaemia longer than two
months, a lower rate of pCR was observed (16% vs 29%,
p=0.03 and 16% vs 25%, p=0.01, respectively). Patients
with both these characteristics had the lowest rate of pCR
(10%, p=0.01).
• Anaemia is a negative predictive factor for tumor response 
in women treated with NST for BC. 
• This evidence suggests that anaemia should be improved 
in order to improve response to NST. 
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  All patients  No Anaemia Anaemia  p-value 
Characteristics  317  126 191   
        
Age at diagnosis, median (range)  49.5 (26.1-80.2)  50.5 (29.1-80.1) 48.3  (26.1-80.2)  0.905 
Clinical stage       0.933 
I  6  2 (1.6) 4 (2.1)   
II  235  95 (75.4) 140 (73.3)   
III  76  29 (23.0) 47 (24.6)   
BC subtypes       0.710 
Hormone receptors positive  124  46 (36.5) 78 (40.8)   
HER2 positive  111  47 (37.3) 64 (33.5)   
Triple negative   82  33 (26.2) 49 (25.7)   
Grade       0.723 
1-2  37  9 (7.1) 28 (14.7)   
3  280  117 (92.9) 163 (85.3)   
Neoadjuvant chemotherapy       0.132 
Anthracycline  26  16 (12.7) 10 (5.2)   
Anthracycline + Taxane  259  98 (77.8) 161 (84.3)   
Taxane  9  3 (2.4) 6 (3.1)   
Platinum + Taxane  23  9 (7.1) 14 (7.3)   
Pre-treatment anaemia       <0.0001 
Absent  286  126 (100) 160 (83.8)   
Present  31  0 31 (16.2)   
 
Patients’ characteristics
• 83 patients (26%) achieved
pCR.
• pCR rate was not influenced
by baseline Hb level.
• Anaemia was an
independent negative
predictive factor for pCR in
univariate and multivariate
analysis (p=0.009).
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